Silent battles: immune responses in asymptomatic SARS-CoV-2 infection
N Le Bert, T Samandari - Cellular & Molecular Immunology, 2024 - nature.com
SARS-CoV-2 infections manifest with a broad spectrum of presentations, ranging from
asymptomatic infections to severe pneumonia and fatal outcomes. This review centers on …
asymptomatic infections to severe pneumonia and fatal outcomes. This review centers on …
[HTML][HTML] Trends in laboratory-confirmed SARS-CoV-2 reinfections and associated hospitalizations and deaths among adults aged≥ 18 years—18 US jurisdictions …
KC Ma - MMWR. Morbidity and Mortality Weekly Report, 2023 - cdc.gov
During September 2021–December 2022, the percentages of reinfections among all COVID-
19 cases, hospitalizations, and deaths reported by 18 US jurisdictions increased …
19 cases, hospitalizations, and deaths reported by 18 US jurisdictions increased …
Leveraging donor populations to study the epidemiology & pathogenesis of transfusion-transmitted and emerging infectious diseases
The tragedy of transfusion-associated hepatitis and HIV spurred a decades-long overhaul of
the regulatory oversight and practice of blood transfusion. Consequent to improved donor …
the regulatory oversight and practice of blood transfusion. Consequent to improved donor …
[HTML][HTML] Interim recommendations for use of bivalent mRNA COVID-19 vaccines for persons aged≥ 6 months—United States, April 2023
DL Moulia - MMWR. Morbidity and Mortality Weekly Report, 2023 - cdc.gov
During December 2022–April 2023, CDC made recommendations for a single bivalent
vaccine dose for most persons aged≥ 6 years, bivalent vaccines for children aged 6 months …
vaccine dose for most persons aged≥ 6 years, bivalent vaccines for children aged 6 months …
Safety and immunogenicity of the monovalent omicron XBB. 1.5-adapted BNT162b2 COVID-19 vaccine in individuals≥ 12 years old: a phase 2/3 trial
J Gayed, O Diya, FS Lowry, X Xu, V Bangad, F Mensa… - Vaccines, 2024 - mdpi.com
Vaccination remains an important mitigation tool against COVID-19. We report 1-month
safety and preliminary immunogenicity data from a substudy of an ongoing, open-label …
safety and preliminary immunogenicity data from a substudy of an ongoing, open-label …
Combining genomic data and infection estimates to characterize the complex dynamics of SARS-CoV-2 Omicron variants in the US
Omicron surged as a variant of concern in late 2021. Several distinct Omicron variants
appeared and overtook each other. We combined variant frequencies and infection …
appeared and overtook each other. We combined variant frequencies and infection …
The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States
MA Kohli, M Maschio, K Joshi, A Lee… - Journal of Medical …, 2023 - Taylor & Francis
Aims To assess the potential clinical impact and cost-effectiveness of COVID-19 mRNA
vaccines updated for fall 2023 in adults aged≥ 18 years over a 1-year analytic time horizon …
vaccines updated for fall 2023 in adults aged≥ 18 years over a 1-year analytic time horizon …
Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial
Abstract In the phase 3 Coronavirus Efficacy (COVE) trial (NCT04470427), post-dose two
Ancestral Spike-specific binding (bAb) and neutralizing (nAb) antibodies were shown to be …
Ancestral Spike-specific binding (bAb) and neutralizing (nAb) antibodies were shown to be …
[HTML][HTML] Development of COVID-19 vaccine policy—United States, 2020–2023
SE Oliver, M Wallace, E Twentyman, DL Moulia… - Vaccine, 2024 - Elsevier
COVID-19 vaccines represent a great scientific and public health achievement in the face of
overwhelming pressures from a global pandemic, preventing millions of hospitalizations and …
overwhelming pressures from a global pandemic, preventing millions of hospitalizations and …
COVID-19 point-of-care tests can identify low-antibody individuals: In-depth immunoanalysis of boosting benefits in a healthy cohort
M Mallory, JE Munt, TM Narowski, I Castillo… - Science …, 2024 - science.org
The recommended COVID-19 booster vaccine uptake is low. At-home lateral flow assay
(LFA) antigen tests are widely accepted for detecting infection during the pandemic. Here …
(LFA) antigen tests are widely accepted for detecting infection during the pandemic. Here …